Analysts expect Equillium (NYSE:EQ) to post earnings per share of ($0.27) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Equillium’s earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.31). The firm is scheduled to announce its next earnings report on Wednesday, June 26th.
According to Zacks, analysts expect that Equillium will report full-year earnings of ($1.36) per share for the current financial year, with EPS estimates ranging from ($1.67) to ($1.09). For the next financial year, analysts expect that the business will report earnings of ($1.72) per share, with EPS estimates ranging from ($2.30) to ($1.34). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Equillium.
Equillium (NYSE:EQ) last posted its quarterly earnings results on Wednesday, March 27th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.02).
A number of research analysts have commented on EQ shares. Zacks Investment Research upgraded Equillium from a “sell” rating to a “hold” rating in a research note on Wednesday, January 16th. Svb Leerink restated an “outperform” rating and issued a $16.00 target price on shares of Equillium in a research note on Friday, February 22nd. Finally, Leerink Swann started coverage on Equillium in a research note on Friday, February 22nd. They issued an “outperform” rating on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $19.00.
NYSE:EQ opened at $6.08 on Monday. Equillium has a 1-year low of $5.12 and a 1-year high of $19.69.
A number of hedge funds and other institutional investors have recently modified their holdings of EQ. BlackRock Inc. bought a new stake in shares of Equillium during the 4th quarter worth about $1,756,000. Partner Investment Management L.P. bought a new stake in shares of Equillium during the 4th quarter worth about $64,000. American International Group Inc. bought a new stake in shares of Equillium during the 4th quarter worth about $28,000. Asymmetry Capital Management L.P. bought a new stake in shares of Equillium during the 4th quarter worth about $497,000. Finally, Partner Fund Management L.P. bought a new stake in shares of Equillium during the 4th quarter worth about $11,049,000.
Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.
Further Reading: Do stock splits help investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.